Selection of an Optimal In Vitro Model to Assess P-gp Inhibition: Comparison of Vesicular and Bidirectional Transcellular Transport Inhibition Assays

被引:3
|
作者
Yabut, Jocelyn [1 ]
Houle, Robert [1 ]
Wang, Shubing [2 ]
Liaw, Andy [2 ]
Katwaru, Ravi [1 ]
Collier, Hannah [1 ]
Hittle, Lucinda [1 ]
Chu, Xiaoyan [1 ]
机构
[1] Merck & Co Inc, Dept Pharmacokinet Pharmacodynam & Drug Metab, Kenilworth, NJ USA
[2] Merck & Co Inc, Dept Biometr Res, Kenilworth, NJ USA
关键词
DRUG-DRUG INTERACTION; CLASSIFICATION-SYSTEM; GLYCOPROTEIN; DIGOXIN; FEXOFENADINE; DISPOSITION; PREDICTION; SUBSTRATE; CRITERIA; BCS;
D O I
10.1124/dmd.121.000807
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The multidrug resistance protein 1 (MDR1) P-glycoprotein (P-gp) is a clinically important transporter. In vitro P-gp inhibition assays have been routinely conducted to predict the potential for clinical drug-drug interactions (DDIs) mediated by P-gp. However, high interlaboratory and intersystem variability of P-gp IC50 data limits accurate prediction of DDIs using static models and decision criteria recommended by regulatory agencies. In this study, we calibrated two in vitro P-gp inhibition models: vesicular uptake of N-methyl-quinidine (NMQ) in MDR1 vesicles and bidirectional transport (BDT) of digoxin in Lilly Laboratories Cell Porcine Kidney 1 cells overexpressing MDR1 (LLC-MDR1) using a total of 48 P-gp inhibitor and noninhibitor drugs and digoxin DDI data from 70 clinical studies. Refined thresholds were derived using receiver operating characteristic analysis, and their predictive performance was compared with the decision frameworks proposed by regulatory agencies and selected reference. Furthermore, the impact of various IC50 calculation methods and nonspecific binding of drugs on DDI prediction was evaluated. Our studies suggest that the concentration of inhibitor based on highest approved dose dissolved in 250 ml divided by IC50 (I-2/IC50) is sufficient to predict P-gp related intestinal DDIs. IC50 obtained from vesicular inhibition assay with a refined threshold of I-2/IC50 >= 25.9 provides comparable predictive power over those measured by net secretory flux and efflux ratio in LLC-MDR1 cells. We therefore recommend vesicular P-gp inhibition as our preferred method given its simplicity, lower variability, higher assay throughput, and more direct estimation of in vitro kinetic parameters, rather than BDT assay. SIGNIFICANCE STATEMENT This study has conducted comprehensive calibration of two in vitro P-gp inhibition models: uptake in MDR1 vesicles and bidirectional transport in LLC-MDR1 cell monolayers to predict DDIs. This study suggests that IC(50)s obtained from vesicular inhibition with a refined threshold of I-2/IC50 >= 25.9 provide comparable predictive power over those in LLC-MDR1 cells. Therefore, vesicular P-gp inhibition is recommended as the preferred method given its simplicity, lower variability, higher assay throughput, and more direct estimation of in vitro kinetic parameters.
引用
收藏
页码:909 / 922
页数:14
相关论文
共 32 条
  • [1] A P-gp vesicular transport inhibition assay - Optimization and validation for drug-drug interaction testing
    Heredi-Szabo, Krisztina
    Palm, Johan E.
    Andersson, Tommy B.
    Pal, Akos
    Mehn, Dora
    Fekete, Zsolt
    Beery, Erzsebet
    Jakab, Katalin Tauberne
    Jani, Marton
    Krajcsi, Peter
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 49 (04) : 773 - 781
  • [2] A porcine lymphocyte model for P-gp inhibition studies
    Schrickx, J. A.
    Fink-Gremmels, J.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2011, 34 (05) : 499 - 501
  • [3] KINETIC MODEL-BASED DEFINITION FOR CALCULATING P-GP EFFLUX ACTIVITY TO REDUCE THE VARIABILITY OF IN VITRO P-GP INHIBITION POTENCY
    Kishimoto, Wataru
    Ishiguro, Naoki
    Ludwig-Schwellinger, Eva
    Ebner, Thomas
    Maeda, Kazuya
    Yamamura, Norio
    Sugiyama, Yuichi
    DRUG METABOLISM REVIEWS, 2015, 47 : 264 - 264
  • [4] Calcein assay: a high-throughput method to assess P-gp inhibition
    Glavinas, H.
    von Richter, O.
    Vojnits, K.
    Mehn, D.
    Wilhelm, I.
    Nagy, T.
    Janossy, J.
    Krizbai, I.
    Couraud, P.
    Krajcsi, P.
    XENOBIOTICA, 2011, 41 (08) : 712 - 719
  • [5] RELEVANCE AND VALUE OF IN VITRO P-GP INHIBITION DATA FOR NEW MOLECULAR ENTITIES
    Agarwal, S.
    Zhang, L.
    Huang, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S40 - S40
  • [6] Comparison of two functional flow cytometric assays to assess P-gp activity in acute leukemia
    Swerts, K
    De Moerloose, B
    Dhooge, C
    Noens, L
    Laureys, G
    Benoit, Y
    Philippe, J
    LEUKEMIA & LYMPHOMA, 2004, 45 (11) : 2221 - 2228
  • [7] A phase I drug-drug interaction study to assess the effect of futibatinib on P-gp and BCRP substrates and of P-gp inhibition on the pharmacokinetics of futibatinib
    Long, Amanda
    Yamamiya, Ikuo
    Valentine, Michelle
    Machnes, Ziv
    Hangai, Nanae
    Anderson, Bailey
    Wacheck, Volker
    Gao, Ling
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (09):
  • [8] P-gp efflux pump inhibition potential of common environmental contaminants determined in vitro
    Georgantzopoulou, Anastasia
    Skoczynska, Ewa
    van den Berg, Johannes H. J.
    Brand, Walter
    Legay, Sylvain
    Klein, Sebastian G.
    Rietjens, Ivonne M. C. M.
    Murk, Albertinka J.
    ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY, 2014, 33 (04) : 804 - 813
  • [9] Transport Inhibition of Digoxin Using Several Common P-gp Expressing Cell Lines Is Not Necessarily Reporting Only on Inhibitor Binding to P-gp
    Lumen, Annie Albin
    Li, Libin
    Li, Jiben
    Ahmed, Zeba
    Meng, Zhou
    Owen, Albert
    Ellens, Harma
    Hidalgo, Ismael J.
    Bentz, Joe
    PLOS ONE, 2013, 8 (08):
  • [10] Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P-gp Inhibition
    Chu, Xiaoyan
    Galetin, Aleksandra
    Zamek-Gliszczynski, Maciej J.
    Zhang, Lei
    Tweedie, Donald J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (05) : 788 - 792